In 2015, the first biosimilar was approved in the U.S., and there are more than 50 biosimilars on the way. Their introduction may help expand access to high-quality treatment options for clinicians and patients and may reduce costs to families, caregivers, payers, and the health care system.

The Biosimilars Forum provides evidence-based information to educate and engage everyone involved—health care providers, payers, regulators, policymakers, patient advocates, and patients. The Biosimilars Forum will provide clear, unbiased information to help stakeholders better understand biosimilars and make wise decisions on policy and use.

Below is content on the pressing issues concerning policies, regulatory comments, FDA resources, and research that may encourage access, awareness, and adoption of biosimilars.

Biosimilars Forum Statements:

  • For the Biosimilars Forum’s statements regarding items of interest to the biosimilars community, please visit our News page.

Links to Biosimilars Information from the FDA:

Biosimilars Forum: State Biosimilars Substitution Compromise

CMS/Biosimilars Reimbursement 

Biosimilars in the News

Coalitions Support for Biosimilars: